Mirum Pharmaceuticals, Inc. - Common Stock (MIRM)

CUSIP: 604749101

Q4 2022 13F Holders as of 31 Dec 2022

Holder snapshot 7 signals
Share change
-461,012
Put/Call ratio
32%
SEC-reported price per share
$19.50
Number of holders
101
Value change
-$12,725,497
Number of buys
59
Open additional details 1 more signal available
Number of sells
47
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
60,919,423

Security key

604749101

Report period

Q4 2022

Institutions

101

Top holders

10

Ownership snapshot

Top reported holders of MIRM - Mirum Pharmaceuticals, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
James E. Flynn
Disclosed value leader
James E. Flynn
Comparable rows
0/15
Latest evidence
11 Nov 2022
3/4/5 13F Highest disclosed value: $90,958,032 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

James E. Flynn has the largest disclosed position value at $90.96M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens James E. Flynn's linked filing trail.
Disclosed position value Top 5
James E. Flynn $90.96M
NEA Management Company, LLC $87.99M
Frazier Life Sciences Management,... $80.42M
Niall O'Donnell $45.45M
DEERFIELD MANAGEMENT COMPANY, L.P. $42.7M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
James E. Flynn
3/4/5
* Possible Member of 10% Group, 10%+ Owner
—
denominator unverified
$90,958,032
3,244,434 shares
— 06 Jun 2022
NEA Management Company, LLC
13F
Company
13F
—
denominator unverified
$87,986,000
4,187,801 shares
— 30 Sep 2022
Frazier Life Sciences Management, L.P.
13F
Company
13F
—
denominator unverified
$80,422,000
3,827,781 shares
— 30 Sep 2022
Niall O'Donnell
3/4/5
Director
—
denominator unverified
$45,448,205
1,621,118 shares
— 11 Nov 2022
DEERFIELD MANAGEMENT COMPANY, L.P.
13F
Company
13F
—
denominator unverified
$42,699,000
2,032,335 shares
— 30 Sep 2022
RiverVest Venture Management LLC
13F
Company
13F
—
denominator unverified
$40,363,000
1,921,118 shares
— 30 Sep 2022
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q4 2022

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
101
Shares
33,331,988
Rows available
101
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q4 2022 vs Q3 2022 Across Filers

Q3 2022 holders
107
Q4 2022 holders
101
Holder diff
-6
Investor Q3 2022 Shares Q4 2022 Shares Share Diff Share Chg % Q3 2022 value Q4 2022 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .